Research article · 15 Apr 2026
Conference abstractPublished 29 Jul 2013
Vasoactive intestinal peptide-treated bone marrow dendritic cells ameliorate adriamycininduced nephropathy
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
D endritic cells (DCs) are professional antigen presenting cells, which play an important role in triggering adaptive immune response, and bone marrow DCs have been shown to accumulate in tubulo and periglomerular interstitium in lupus nephritis and glomerulonephritis, and rat crescentic glomerulonephritis. Murine bone marrow DCs can be modified by Vasoactive Intestinal Peptide (VIP), a neuropeptide found in ovarian nerves, to VIP-modified dendritic cells (VIP-Dregs) with tolerogenic properties. VIP-Dregs have been widely reported as treatment for experimental autoimmune diseases, including EAE and host- versus-graft rejection. Now we investigated an effect of VIP-Dregs in protection against renal injury in the Adriamycin-induced murine model of chronic kidney diseases. Bone marrow DCs derived from BALB/c mice were modulated in vitro with Apoptotic cells (1 million/ml) into VIP-Dregs. Mice underwent ex vivo adoptive transfer with 1 million VIP-Dregs/per mice. After 4 weeks, these VIP-Dregs localized to the kidney cortex and lymph nodes draining the kidney, and protected the kidney from injury during adriamycin nephropathy. Histologically, glomerulosclerosis, tubular atrophy, interstitial expansion, proteinuria, and creatinine clearance were significantly reduced in mice with adriamycin nephropathy subsequently treated with VIP-Dregs. Additionally, VIP-Dregs convert CD4+CD25+ T cells into Foxp3+ regulatory T cells and suppress the proinflammatory cytokine production of endogenous renal macrophages. This may explain their ability to protect against renal injury in adriamycin nephropathy.
Subjects
Nephrology & UrologyAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Journal of Nephrology & Therapeutics.
Brief report · 30 Mar 2026
Renal Fibrosis: Targeting Pathways For New Therapies
Brief report · 30 Mar 2026
SGLT2 Inhibitors: A New Era for Diabetic Kidney Disease
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Nephrology & Therapeutics
- SubjectNephrology & Urology
- BylineArticles whose byline prints “Dong Zheng”
- BylineArticles whose byline prints “Lei Wen”
- BylineArticles whose byline prints “Xinhua Li”
- BylineArticles whose byline prints “Ai Peng”
